News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Astellas Pharma Inc. Withdraws Japan Filing for Darexaban, Looks for Partners
February 16, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Pharma Times -- Astellas Pharma has pulled its filing in Japan for its oral Factor Xa inhibitor darexaban after regulators said they needed to see more data.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Astellas Pharma US, Inc.
MORE ON THIS TOPIC
Government
Hundreds of HHS Staffers Accuse RFK Jr. of ‘Sowing Public Mistrust’ Against CDC After Shooting at HQ
August 21, 2025
·
2 min read
·
Tristan Manalac
Regulatory
Two FDA Decisions for Regeneron’s Eylea HD Delayed Into Q4
August 21, 2025
·
2 min read
·
Tristan Manalac
Cancer
FDA Looks To Raise Survival Bar for Cancer Drug Approvals in New Draft Guidance
August 20, 2025
·
2 min read
·
Tristan Manalac
Vaccines
American Academy of Pediatrics Contradicts CDC, Recommends COVID-19 Shot for Kids
August 20, 2025
·
2 min read
·
Tristan Manalac
